Table 3.

Longitudinal follow-up of serum miRNA levels during 8 years in DaT-negative and DaT-positive L2NMC with respect to their baselines.

	DaT-negative L2NMC				DaT-positive L2NMC
MicroRNA	Time point 2 (n = 18)		Time point 3 (n = 16)		Time point 2 (n = 16)		Time point 3 (n = 13)
	FC	Adj. p	FC	Adj. p	FC	Adj. p	FC	Adj. p
miR-122-5p	1.30	0.5467	2.74	0.0117	1.66	0.3585	3.57	0.0190
miR-16-5p	6.12	4.0 × 10−6	12.71	<1.0 × 10−6	5.43	0.0002	17.94	<1.0 × 10−6
miR-185-5p	1.40	0.1996	3.73	0.0002	−1.22	0.5354	3.35	0.0005
miR-19b-3p	5.60	<1.0 × 10−6	15.40	<1.0 × 10−6	3.25	0.0055	15.72	<1.0 × 10−6
miR-22-3p	2.99	3.5 × 10−5	7.48	<1.0 × 10−6	2.39	0.0087	8.06	<1.0 × 10−6
miR-221-3p	1.39	0.1996	2.90	0.0005	2.16	0.0273	5.39	2.0 × 10−6
miR-29c-3p	3.02	0.0001	7.09	<1.0 × 10−6	1.54	0.2551	7.55	1.0 × 10−6
miR-3196	1.11	0.5663	−1.09	0.5548	1.46	0.1274	1.21	0.3083
miR-4505	−1.89	0.0015	−1.16	0.4436	−1.25	0.0068	−1.54	0.1144
miR-451a	2.85	0.0017	5.05	2.5 × 10−5	2.42	0.0273	6.60	3.0 × 10−6
miR-6125	6.75	<1.0 × 10−6	5.81	1.0 × 10−6	5.51	0.0002	5.46	7.0 × 10−6
miR-8069	−1.72	0.0004	−1.89	0.0006	−1.43	0.0879	−1.47	0.0709

RT-qPCR analysis comparing time point 2 and 3 of DaT-negative and DaT-positive L2NMC groups with their respective baselines.

DaT DaT-SPECT imaging, L2NMC LRRK2 non-manifesting carriers, L2PD LRRK2-associated PD patients, iPD idiopathic PD patients, FC fold change, Adj. p FDR multiple-test adjusted p value.